Figure 4.
A) FZD 1/2 expression at baseline prior to selumetinib therapy; B) Elevated FZD 1/2 expression post treatment with selumetinib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.